Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTABLETGeneric

SITAGLIPTIN AND METFORMIN HCL

SITAGLIPTIN, METFORMIN HYDROCHLORIDE

Standard Dose
EQ 100MG BASE TABLET
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview SITAGLIPTIN AND METFORMIN HCL is listed in Drugs@FDA under application 218971 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient SITAGLIPTIN, METFORMIN HYDROCHLORIDE Form and strength TABLET - EQ 100MG BASE TABLET Sponsor MANKIND PHARMA LTD Submission history Latest submission status date: 2024-12-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview SITAGLIPTIN AND METFORMIN HCL is listed in Drugs@FDA under application 218971 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient SITAGLIPTIN, METFORMIN HYDROCHLORIDE Form and strength TABLET - EQ 100MG BASE TABLET Sponsor MANKIND PHARMA LTD Submission history Latest submission status date: 2024-12-11 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.